KRN-5500
- Generic Name
- KRN-5500
- Drug Type
- Small Molecule
- Chemical Formula
- C28H43N7O7
- CAS Number
- 151276-95-8
- Unique Ingredient Identifier
- 8VH13L5K20
- Background
KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).
Neuropathic Pain in Patients With Cancer
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- DARA Therapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT00474916
- Locations
- 🇺🇸
Cancer Institute Medical Group, Los Angeles, California, United States
🇺🇸University of California / Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Hematology and Oncology Specialists, LLC, Covington, Louisiana, United States
KRN5500 in Treating Patients With Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00002923
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
KRN5500 in Treating Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Other: pharmacological study
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00017238
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath